AUS
NZ
UK
CA
USA
IND
Highlights
- BXB shares have gained nearly 20% YTD amid stable dividend performance
- COH shares hover over 23% above 52-week low with growth valuation metrics
- Both stocks show a valuation below their respective long-term yield and ratio averages
Investors often seek simple yet effective ways to understand the value of company shares. Two prominent ASX-listed businesses—Brambles (BXB) and Cochlear (COH)—offer distinct opportunities for examining value through the lens of historical metrics and operational strength.
Brambles (ASX:BXB): A Global Supply Chain Engine
Brambles operates a vast logistics ecosystem, renowned for managing the world's largest pool of reusable pallets, crates, and containers. Its primary brand, CHEP, facilitates operations across key global regions, including Asia-Pacific, the Americas, and EMEA.
The Brambles model is built on efficiency. Instead of selling pallets, the company rents them to manufacturers and retailers, generating steady income through daily hire fees as items move along the supply chain.
In 2025, Brambles shares have climbed approximately 19.8%, drawing attention from investors interested in dividend income and business resilience. One quick method to assess its valuation is through dividend yield trends. As of now, the stock's yield stands at 2.19%, which trails the 5-year average of 2.66%.
This divergence suggests BXB shares are currently trading at a relatively higher price point, assuming dividends have remained steady or grown. Notably, the company’s latest annual report confirmed an increase in dividends compared to its 3-year average, which indicates underlying strength in its payout capability.
Cochlear (ASX:COH): Leading in Hearing Innovation
Cochlear, founded in Sydney in 1981, is a pioneer in implantable hearing solutions. With over 750,000 devices supplied globally and a workforce of 5,000 across 50+ countries, it remains a key player in the global medtech sector.
The COH share price is currently around 23.3% higher than its 52-week low. To assess Cochlear’s market valuation, the price-to-sales (P/S) ratio offers a useful snapshot. Presently, COH trades at 8.88x sales, which is slightly below its 5-year average of 9.18x.
This suggests the current price is modest in comparison to its historical valuation, despite the company’s strong growth positioning. The P/S ratio provides insight into how much the market is paying for each dollar of Cochlear’s revenue, and a value below the long-term average can indicate potential investor value.
Both Brambles and Cochlear offer contrasting yet compelling business models—one grounded in supply chain logistics and the other in advanced medical technology. While Brambles provides stability through dividends, Cochlear reflects long-term growth driven by innovation. Their valuation metrics indicate room for continued market interest, particularly for those tracking performance trends over time.
